Medpace Holdings – CRO Asset Evaluation, Competitive Analysis & Strategic Business Scalability Opportunities

  • Public Equity
  • Healthcare
  • North America


Former director at Medpace Holdings Inc


  • CRO (contract research organisation) operating environment post the biotech funding slowdown and subsequent impact on Medpace’s (NASQ: MEDP) positioning
  • Service offering analysis across early and late stage clinical trials – DCT (decentralised clinical trial) offerings, C&GT (cell and gene therapy) research, bioanalytical capabilities and oncology and neurology pipeline among many others
  • Competitive landscape for Medpace vs other CROs, noting key points of differentiation such as its one-stop shop offering, science-oriented leadership team and unique partnerships
  • Expectations for Q4 2022 results, focusing on backlog conversion rates, projected revenue growth, customer adoption and new revised guidance
  • Medpace’s 6-12-month growth trajectory, discussing elbow room for potential M&A and capitalisation opportunities


Gain access to Premium Content

Submit your details to access up to 5 Forum Transcripts or to request a complimentary one week trial.

    One week, unlimited access to over 40,000 transcripts
The information, material and content contained in this transcript (“Content”) is for information purposes only and does not constitute advice of any type or a trade recommendation and should not form the basis of any investment decision.This transcript has been edited by Third Bridge for ease of reading. Third Bridge Group Limited and its affiliates (together “Third Bridge”) make no representation and accept no liability for the Contentor for any errors, omissions or inaccuracies in respect of it. The views of the specialist expressed in the Content are those of the specialist and they are not endorsed by, nor do they represent the opinion of, Third Bridge. Third Bridge reserves all copyright, intellectual and other property rights in the Content. Any modification, reformatting, copying, displaying, distributing, transmitting, publishing, licensing, creating derivative works from, transferring or selling any Content is strictly prohibited